Get started
Author

Agneta Wennerholm

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*
1998 · Karin Herrlin, Amos Y. Massele, et al. · Clinical Pharmacology & Therapeutics · 95
The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity
2001 · Agneta Wennerholm, Collet Dandara, et al. · Clinical Pharmacology & Therapeutics · 93
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
2006 · Rajaa A. Mirghani, Jane Sayi, et al. · Pharmacogenetics and Genomics · 86
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
1999 · Maria Luisa Bernal, Blanca Sinues, et al. · Pharmacogenetics · 82
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity
2001 · Agneta Wennerholm, Inger Johansson, et al. · Pharmacogenetics · 78
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
1999 · A Wennerholm, I Johansson, et al. · PubMed · 75
Decreased capacity for debrisoquine metabolism among black Tanzanians
1999 · Agneta Wennerholm, Inger Johansson, et al. · Pharmacogenetics · 58
Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations
2002 · �mit Yasar, Eleni Aklillu, et al. · European Journal of Clinical Pharmacology · 53
Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo
2006 · Agneta Wennerholm, Anna Nordmark, et al. · European Journal of Clinical Pharmacology · 30
Simultaneous quantification of alprazolam, 4- and α-hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry
2004 · Annika Allqvist, Agneta Wennerholm, et al. · Journal of Chromatography B · 20
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects
2005 · Agneta Wennerholm, Annika Allqvist, et al. · European Journal of Clinical Pharmacology · 18
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
1999 · Maria Luisa Bernal, Blanca Sinues, et al. · Pharmacogenetics and Genomics · 2
Decreased capacity for debrisoquine metabolism among black Tanzanians
1999 · Agneta Wennerholm, Inger Johansson, et al. · Pharmacogenetics and Genomics · 1
First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients
2026 · Anouk C Meijs, Johan Kolmert, et al. · RMD Open
PDF
CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo
2006 · J. Miura, E. Aklillu, et al. · International Clinical Psychopharmacology
Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population
2003 · Agneta Wennerholm · Figshare
Works count: 16
Citation count: 690
H-index: 11
I10-index: 11
Year
Topic
Type